The new frontiers of DMT therapies
The new frontiers of DMT therapies
Business Trip, a podcast about psychedelic entrepreneurship
Welcome back to Business Trip, a podcast about psychedelic entrepreneurship! 🍄
In Episode 11, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. Much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, but we wanted to know how a company goes about starting a drug development program for indications outside of what most companies are working on. The episode features three biotech companies developing novel DMT therapies: Algernon, Psilera, and Pharmadrug.
In this episode, we discuss:
DMT therapies for organ transplants, stroke patients and substance abuse disorders
Research supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targets
Being a private company vs. public company in psychedelics
What is orphan drug designation and how to apply for it
Listen to the episode here, on Spotify or Apple Podcasts.
When you’re done listening, tweet at us @businesstripfm to share your thoughts!
About Us
Business Trip tells the story of the emerging industry of psychedelics. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re advocates of the healing powers of psychedelic medicine and see a bright future ahead for the industry.
Thanks for listening,
💖 Know someone who would enjoy Business Trip?